These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 9234721)
1. Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics. Eng FC; Lee HS; Ferrara J; Willson TM; White JH Mol Cell Biol; 1997 Aug; 17(8):4644-53. PubMed ID: 9234721 [TBL] [Abstract][Full Text] [Related]
2. Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain. Eng FC; Barsalou A; Akutsu N; Mercier I; Zechel C; Mader S; White JH J Biol Chem; 1998 Oct; 273(43):28371-7. PubMed ID: 9774463 [TBL] [Abstract][Full Text] [Related]
3. Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. Aumais JP; Lee HS; Lin R; White JH J Biol Chem; 1997 May; 272(18):12229-35. PubMed ID: 9115298 [TBL] [Abstract][Full Text] [Related]
4. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652 [TBL] [Abstract][Full Text] [Related]
5. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Métivier R; Penot G; Flouriot G; Pakdel F Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626 [TBL] [Abstract][Full Text] [Related]
6. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Devin-Leclerc J; Meng X; Delahaye F; Leclerc P; Baulieu EE; Catelli MG Mol Endocrinol; 1998 Jun; 12(6):842-54. PubMed ID: 9626660 [TBL] [Abstract][Full Text] [Related]
7. Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands. Reese JC; Katzenellenbogen BS J Biol Chem; 1991 Jun; 266(17):10880-7. PubMed ID: 2040605 [TBL] [Abstract][Full Text] [Related]
8. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783 [TBL] [Abstract][Full Text] [Related]
9. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Metzger D; Berry M; Ali S; Chambon P Mol Endocrinol; 1995 May; 9(5):579-91. PubMed ID: 7565805 [TBL] [Abstract][Full Text] [Related]
10. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo. Wang H; Peters GA; Zeng X; Tang M; Ip W; Khan SA J Biol Chem; 1995 Oct; 270(40):23322-9. PubMed ID: 7559488 [TBL] [Abstract][Full Text] [Related]
11. Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain. Métivier R; Petit FG; Valotaire Y; Pakdel F Mol Endocrinol; 2000 Nov; 14(11):1849-71. PubMed ID: 11075817 [TBL] [Abstract][Full Text] [Related]
12. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Knoblauch R; Garabedian MJ Mol Cell Biol; 1999 May; 19(5):3748-59. PubMed ID: 10207098 [TBL] [Abstract][Full Text] [Related]
13. Hormone-dependent transactivation by estrogen receptor chimeras that do not interact with hsp90. Evidence for transcriptional repressors. Lee HS; Aumais J; White JH J Biol Chem; 1996 Oct; 271(42):25727-30. PubMed ID: 8824196 [TBL] [Abstract][Full Text] [Related]
14. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Tremblay GB; Tremblay A; Copeland NG; Gilbert DJ; Jenkins NA; Labrie F; Giguère V Mol Endocrinol; 1997 Mar; 11(3):353-65. PubMed ID: 9058381 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327 [TBL] [Abstract][Full Text] [Related]
16. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465 [TBL] [Abstract][Full Text] [Related]
17. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes. Liu S; Han SJ; Smith CL Mol Pharmacol; 2013 May; 83(5):1066-77. PubMed ID: 23462505 [TBL] [Abstract][Full Text] [Related]
18. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965 [TBL] [Abstract][Full Text] [Related]